Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Actio Biosciences

News headline image
Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Participate in TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Participate in Evercore Emerging Private Biotech Conference
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-0871, a Novel TRPV4 Inhibitor, for the Treatment of Charcot Marie Tooth Disease 2C
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Participate in Upcoming Investor Conferences
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Expands Leadership Team with Appointment of Cayce Denton as Chief Financial Officer
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Participate in Upcoming Investor Conferences
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences to Participate in Upcoming October Investor Conferences
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Appoints Dimitrios Arkilo, M.D., Experienced Neurologist and Epileptologist, as Chief Medical Officer
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Receives Orphan Drug and Rare Pediatric Disease Designations for ABS-0871 for the Treatment of Charcot-Marie-Tooth Disease 2C
From Actio Biosciences
Via Business Wire
News headline image
Renowned Rare-Disease Drug Developer Emil Kakkis, M.D., Ph.D., to Join Actio Biosciences Board of Directors
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Appoints Samuel Collins, MBBS, Ph.D., MBA, as Chief Medical Officer as Company Advances Multiple Precision Medicine Programs Toward Clinical Development
From Actio Biosciences
Via Business Wire
News headline image
Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases
From Actio Biosciences
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.